Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab Announces Update on Zalutumumab18 Oct 2010
Grant of Warrants to Employees in Genmab14 Oct 2010
Genmab Announces Antibody Development Collaboration with Lundbeck13 Oct 2010
Correction to Major Shareholder Announcement17 Sept 2010
GlaxoSmithKline and Genmab Refocus Development Program for Ofatumumab in Autoimmune Indications16 Sept 2010
Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration14 Sept 2010
Genmab Updates Corporate Strategy14 Sept 2010
Major Shareholder Announcement
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
13 Sept 2010
Genmab Announces Results of Ofatumumab Phase II Study in Multiple Sclerosis10 Sept 2010
Genmab to Present at Two Investor Conferences in September8 Sept 2010
GSK and Genmab Announce Start of Ofatumumab Phase III Combination Study in Non-Hodgkin's Lymphoma8 Sept 2010
Interim Report for the 6 months ended June 30, 201017 Aug 2010
  • Previous
  • 1
  • More pages
  • 99
  • 100
  • 101
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863